On The Fly: Top five analyst upgrades

Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Pfizer (PFE) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst David Risinger saying he believes investors underappreciate the global prospects for breast cancer drug Ibrance, which he expects to maintain its first-to-market advantage. 2. Progressive (PGR) upgraded to Neutral from Underperform at Credit Suisse with analyst Ryan Tunis citing the announcement of much lower than expected Harvey losses of approximately $230M versus his estimate of $550M. 3. American Airlines (AAL) and Southwest (LUV) were upgraded to Outperform from Market Perform at Raymond James. 4. Post Holdings (POST) upgraded to Outperform from Market Perform at BMO Capital with analyst Kenneth Zaslow saying he expects the company to be boosted by egg price increases. 5. Nordson (NDSN) upgraded to Buy from Neutral at Longbow with analyst Christopher Dankert saying ATS growth concerns are overblown and views valuation as attractive. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.